ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas

Comment

Douglas B Evans et al. Ann Surg. 2002 Nov.

. 2002 Nov;236(5):694; author reply 694-6.

doi: 10.1097/01.SLA.0000037256.09376.FC.

No abstract available

Comment on

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Büchler MW; European Study Group for Pancreatic Cancer. Neoptolemos JP, et al. Lancet. 2001 Nov 10;358(9293):1576-85. doi: 10.1016/s0140-6736(01)06651-x. Lancet. 2001. PMID: 11716884 Clinical Trial.
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.
Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Lacaine F, Buckels J, Deakin M, Adab FA, Sutton R, Imrie C, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, Büchler MW; European Study Group for Pancreatic Cancer. Neoptolemos JP, et al. Ann Surg. 2001 Dec;234(6):758-68. doi: 10.1097/00000658-200112000-00007. Ann Surg. 2001. PMID: 11729382 Free PMC article. Clinical Trial.

1. Neoptolemos JP, Stocken DD, Dunn JA, et al. The influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234 (6): 758–768. - PMC - PubMed
1. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576–1585. - PubMed